Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients.

ABSTRACT:

Background

Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we examined the correlation patterns of Decipher assay to understand the relationship between the Decipher and patient tumor characteristics.

Methods

De-identified Decipher test results (including Decipher risk scores and clinicopathologic data) from 2 342 consecutive radical prostatectomy (RP) patients tested between January and September 2015 were analyzed. For clinical testing, tumor specimen from the highest Gleason grade was sampled using a 1.5 mm tissue punch. De

SUBMITTER: Den RB 

PROVIDER: S-EPMC5133268 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature